Idiopathic Cervical Dystonia Clinical Trial
— RINOCERAUSOfficial title:
Results of Botulinum Toxin Injections for Cervical Dystonia : Benefits of Ultrasonography
| Verified date | April 2021 |
| Source | University Hospital, Lille |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
Botulinum toxin injections are the treatment of choice for cervical dystonia. Even if this treatment is successful for most of the patients, partials or completes failures still remained. Usually, botulinum toxin injections are realized by clinical localization techniques (observation and palpation of target muscles). The use of Ultrasonography to guide injections of Botulinum toxin has theoretical benefits (as an improved precision, an improved reproducibility, the targeting of deep-seated muscles, and a lower risk of adverse events) but its interest has never been demonstrated.
| Status | Completed |
| Enrollment | 132 |
| Est. completion date | April 14, 2020 |
| Est. primary completion date | April 14, 2020 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - Patient older than 18 years old - Focal idiopathic cervical dystonia treated by injections of Botulinum toxin type A (onabotulinumtoxinA, Botox® ; abobotulinumtoxinA, Dysport® ; or incobotulinumtoxinA, Xeomin®). - Patient who have previously received at least 3 cycles of botulinum toxin A injections in this specific indication - Injections realized with clinical targeting exclusively or ultrasonography targeting exclusively - Patient who is not opposed to its participation in this study - Patient affiliated to the Sécurité Sociale - Patient able to comply with study procedures and study duration Exclusion Criteria: - Woman pregnant, woman of childbearing age not taking effective contraception or breastfeeding - Contraindication of botulinum toxin injections as : - Hypersensivity to the botulinum toxin A or to an excipient of the commercialized treatment (onabotulinumtoxinA, Botox® ; abobotulinumtoxinA, Dysport® ; incobotulinumtoxinA, Xeomin®) - Generalized muscular activity disorder (Myasthenia gravis, Lambert-Eaton syndrome) - Infection or inflammation of the injection site - Concomitant treatment that can interact with botulinum toxin A or modify the function of the neuromuscular synapse junction (anticholinergics, curare and other myorelaxing agents, Aminoglycosides, amino-4-quinolines) - Documented resistance to the botulinum toxin A - Inability to receive the information, inability to participate to the all study duration, refusal to sign the consent - EMG-guided botulinum toxin injections |
| Country | Name | City | State |
|---|---|---|---|
| France | Hôpital Roger Salengro, CHRU de Lille - Service de neurologie A | Lille |
| Lead Sponsor | Collaborator |
|---|---|
| University Hospital, Lille |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Cervical Dystonia Impact Profile 58 (CDIP-58) | Variation of the total score obtained with The Cervical Dystonia Impact Profile | 1 month after inclusion | |
| Secondary | Placement of the injecting needle | Assessment of the accurate placement of the injecting needle within the target muscle by ultrasonography in patients injected by the clinical targeting method (number and percent of discordances) | the day of the inclusion | |
| Secondary | GCI-I (Clinical Global Impressions - Improvement) patient scale | Variation of the GCI-I (Clinical Global Impressions - Improvement) patient scale :
= Very much improved : nearly all better; good level of functioning; minimal symptoms; represents a very substantial change = Much improved : notably better with significant reduction of symptoms; increase in the level of functioning but some symptoms remain = Minimally improved : slightly better with little or no clinically meaningful reduction of symptoms. Represents very little change in basic clinical status, level of care, or functional capacity = No change : symptoms remain essentially unchanged = Minimally worse : slightly worse but may not be clinically meaningful; may represent very little change in basic clinical status or functional capacity = Much worse : clinically significant increase in symptoms and diminished functioning = Very much worse : severe exacerbation of symptoms and loss of functioning |
1 month after inclusion | |
| Secondary | TWSTRS-2 (Toronto Western Spasmodic Torticollis Rating Scale) : pain scale only | Variation of the TWSTRS-2 (Toronto Western Spasmodic Torticollis Rating Scale) : pain scale only
Total score = 0 (no pain) to 40 (maximal pain) |
1 month after inclusion | |
| Secondary | TWSTRS-PSYCH (Toronto Western Spasmodic Torticollis Rating Scale - Psychiatric) scale | Variation of the TWSTRS-PSYCH (Toronto Western Spasmodic Torticollis Rating Scale - Psychiatric) scale
Total score = 0 (no psychiatric disorders) to 24 (important psychiatric disorders) |
1 month after inclusion | |
| Secondary | Rate of Adverse Events | Adverse events related to the botulinum toxin injection (pain, swallowing disorders, hematoma, muscular weakness, dry mouth) | 1 month after inclusion |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00833196 -
Factors Influencing Response to One BoNT-A Injection Cycle in Subjects Suffering From Idiopathic Cervical Dystonia
|